Skip to content
Editorial illustration for FDA Approves New Combo Therapy for Stage III dMMR Colon Canc

FDA Approves New Combo Therapy for Stage III dMMR Colon Canc

CancerSnoop News

Atezolizumab approval: The FDA has approved a new treatment combining atezolizumab with chemotherapy to help people with Stage III mismatch repair deficient (dMMR) colon cancer. This offers a fresh option after surgery to prevent the cancer from coming back.

What happened

On October 8, 2026, the FDA approved atezolizumab (Tecentriq) combined with fluoropyrimidine and oxaliplatin chemotherapy for use after surgery in adults and children aged two and older with Stage III dMMR colon cancer. They also approved a shot called Tecentriq Hybreza, which pairs atezolizumab with hyaluronidase, for patients 12 years or older who weigh at least 40 kilograms.

These treatments are given for six months with chemotherapy, then alone for another six months, or until side effects become too severe or the cancer returns. The approval is based on a large clinical trial with 712 patients showing that adding atezolizumab cut the risk of cancer returning by half compared to chemotherapy alone.

Who this concerns

This news is important for patients with Stage III dMMR colon cancer and their families, as well as doctors who care for these patients.

What the evidence shows

The FDA's decision comes from the ATOMIC/ML39057 study involving mostly adults and one child after surgery to remove the tumor. Patients got either the new combination or standard chemotherapy.

The study showed that those receiving atezolizumab plus chemotherapy had much better disease-free survival, meaning their cancer was less likely to return during the study period. The median time without cancer coming back was not yet reached for either group, indicating longer follow-up is needed.

What remains unclear

The recommended doses vary by age, weight, and which drug form is used. The safety information warns about immune system side effects, reactions during infusion, risks related to stem cell transplants, and the potential harm to unborn babies.

The treatment has not been fully studied in patients under 12 years old weighing less than 40 kg. Also, the study mainly included patients after surgery with clear lymph nodes and no spread, so results may not apply to everyone.

Bottom line

Atezolizumab combined with chemotherapy is now FDA-approved to help prevent Stage III dMMR colon cancer from returning after surgery, offering new hope for patients from age two and up. Patients should talk to their doctors about whether this option is right for them.

Official announcement

SHARE THIS EVIDENCE
WhatsApp ↗
Back To Top